Back to Newsroom

Global Genomics Group (G3) And Quintiles, Inc. (Q) Collaborate On Cross-Functional Pan-Omic Study Of Biomarkers And Drug Target Discovery For Cardiovascular Diseases

February 19, 2014 — Global Genomics Group (G3) and Quintiles today announced that they will collaborate to investigate novel biomarkers and biological pathways for use in the development of diagnostic tools and treatments for cardiovascular diseases that impact millions of patients worldwide. Under the terms of the agreement, Expression Analysis (EA), a Quintiles company, will conduct RNA sequencing, microRNA sequencing and methylation analysis in the GLOBAL (Genetic LOci and Burden of Atherosclerotic Lesions) clinical study.